




Instance: composition-en-3441cbef7f1604451bb170e82be4a4ea
InstanceOf: CompositionUvEpi
Title: "Composition for jinarc Package Leaflet"
Description:  "Composition for jinarc Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1ef6cbb5149202df9e76eceb675263a5)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - jinarc"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Jinarc is and what it is used for </li>
<li>What you need to know before you take Jinarc </li>
<li>How to take Jinarc </li>
<li>Possible side effects </li>
<li>How to store Jinarc </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What jinarc is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What jinarc is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Jinarc contains the active substance tolvaptan which blocks the effect of vasopressin, a hormone 
involved in the formation of cysts in the kidneys of ADPKD patients. By blocking the effect of 
vasopressin, Jinarc slows the development of kidney cysts in patients with ADPKD, reduces symptoms 
of the disease and increases urine production. </p>
<p>Jinarc is a medicine used to treat a disease called  autosomal dominant polycystic kidney disease<br />
(ADPKD). This disease causes growth of fluid-filled cysts in the kidneys, which put pressure on 
surrounding tissues and reduce kidney function, possibly leading to kidney failure. Jinarc is used to treat 
ADPKD in adults with chronic kidney disease (CKD) stages 1 to 4 with evidence of rapidly progressing 
disease. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take jinarc"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take jinarc"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Jinarc 
* if you are allergic to tolvaptan or any of the other ingredients of this medicine (listed in section 6) 
or if you are allergic to benzazepine or benzazepine derivatives (e.g. benazepril, conivaptan, 
fenoldopam mesylate or mirtazapine) 
* if you have been told that you have raised levels of liver enzymes in your blood which do not 
allow treatment with tolvaptan 
* if your kidneys do not work (no urine production) 
* if you have a condition which is associated with a very low blood volume (e.g. severe 
dehydration or bleeding) 
* if you have a condition which increases the sodium in your blood 
* if you do not realise when you are thirsty 
* if you are pregnant 
* if you are breastfeeding. </p>
<p>Warnings and precautions 
Talk to your doctor before taking Jinarc 
* if you suffer from liver disease. 
* if you cannot drink enough water (see  drinking enough water  below) or if you have to restrict 
your fluid intake. 
* if you have difficulties urinating (e.g. have an enlarged prostate). 
* if you suffer from too high or too low blood sodium. 
* if you had an allergic reaction in the past to benzazepine, tolvaptan or other benzazepine 
derivatives (e.g. benazepril, conivaptan, fenoldopam mesylate or mirtazapine), or to any of the 
other ingredients of this medicine (listed in section 6). 
* if you have diabetes. 
* if you have been told you have high levels of a chemical called uric acid in your blood (which 
may have caused attacks of gout). 
* if you have advanced kidney disease. </p>
<p>This medicine may cause your liver to not work properly. Therefore, please inform your doctor 
immediately if you have signs that could indicate potential liver problems such as: 
* nausea 
* vomiting 
* fever 
* tiredness 
* loss of appetite 
* pain in the abdomen 
* dark urine 
* jaundice (yellowing of skin or eyes) 
* itching of your skin 
* flu-like syndrome (joint and muscle pain with fever) </p>
<p>During treatment with this medicine, your doctor will arrange monthly blood tests to check for 
changes in your liver function. </p>
<p>Drinking enough water </p>
<p>This medicine causes water loss because it increases your urine production. This water loss may result 
in side effects such as dry mouth and thirst or even more severe side effects like kidney problems (see 
section 4). It is therefore important that you have access to water and that you are able to drink sufficient 
amounts when you feel thirsty. Before bed-time you must drink 1 or 2 glasses of water even if you do 
not feel thirsty and you must also drink water after you urinate at night. Special care must be taken if 
you have a disease that reduces appropriate fluid intake or if you are at an increased risk of water loss 
e.g. in case of vomiting or diarrhoea. Due to the increased urine production, it is also important that you 
always have access to a toilet. </p>
<p>Children and adolescents 
Do not give this medicine to children and adolescents (under age of 18 years) because it has not been 
studied in these age groups. </p>
<p>Other medicines and Jinarc 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, 
including medicines obtained without a prescription. </p>
<p>The following medicines may increase the effect of Jinarc: 
* amprenavir, atazanavir, darunavir/ritonavir and fosamprenavir (used to treat HIV/AIDS), 
* aprepitant (used to avoid nausea and vomiting in chemotherapy), 
* crizotinib and imatinib (used to treat cancer), 
* ketoconazole, fluconazole or itraconazole (used to treat fungal infections), 
* macrolide antibiotics like erythromycin or clarithromycin, 
* verapamil (used to treat heart diseases and high blood pressure), 
* ciprofloxacin (an antibiotic), 
* diltiazem (used to treat high blood pressure and chest pain). </p>
<p>The following medicines may lower the effect of Jinarc: 
* phenytoin or carbamazepine (used to treat epilepsy), 
* rifampicin, rifabutin or rifapentine (used to treat tuberculosis), 
* St. John s Wort (a traditional herbal medicinal product for the relief of slightly low mood and 
mild anxiety). </p>
<p>Jinarc may increase the effect of the following medicines: 
* digoxin (used to treat irregular heart beat and heart failure), 
* dabigatran (used to thin the blood), 
* sulfasalazine (used to treat inflammatory bowel disease or rheumatoid arthritis), 
* metformin (used to treat diabetes). </p>
<p>Jinarc may lower the effect of the following medicines: 
* vasopressin analogues such as desmopressin (used to increase blood clotting factors or to control 
urine output or bedwetting). </p>
<p>These medicines can affect or be affected by Jinarc: 
* diuretics (used to influence the production of urine). Taken with Jinarc these may increase the 
risk of side effects due to water loss or may cause kidney problems. 
* diuretics or other medicines for the treatment of high blood pressure. Taken with Jinarc these may 
increase the risk of low blood pressure when you stand up from sitting or lying down. 
* medicines which increase the level of sodium in your blood or which contain large amounts of 
salt (e.g. tablets that dissolve in water and indigestion remedies). These may increase the effect of 
Jinarc. There is a risk that this may lead to too much sodium in your blood. </p>
<p>It may still be alright for you to take these medicines and Jinarc together. Your doctor will be able to 
decide what is suitable for you. </p>
<p>Jinarc with food and drink 
Do not drink grapefruit juice when taking this medicine. </p>
<p>Pregnancy and breast-feeding 
Do not take this medicine if you are pregnant or breast-feeding. 
Women of childbearing age must use reliable contraceptive measures during use of this medicine. 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>Driving and using machines 
Some people may feel dizzy, weak or tired after being given Jinarc. If this happens to you, do not drive 
or use any tools or machines. </p>
<p>Jinarc contains lactose 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take jinarc"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take jinarc"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Jinarc can only be prescribed by doctors who are specialised in the treatment of ADPKD. Always take 
this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not 
sure. </p>
<p>Dose </p>
<p>The daily amount of Jinarc is split into two doses, one bigger than the other. The higher dose should be 
taken in the morning when you wake up, at least 30 minutes before the morning meal. The lower dose is 
taken 8 hours later. </p>
<p>The dose combinations are: 
45 mg + 15 mg 
60 mg + 30 mg 
90 mg + 30 mg </p>
<p>Your treatment will normally start with a dose of 45 mg in the morning and 15 mg 8 hours later. Your 
doctor may gradually increase your dose up to a maximum combination of 90 mg on waking and 30 mg 
after 8 hours. To find the best dose your doctor will regularly check how well you are tolerating a 
prescribed dose. You should always take the highest tolerable dose combination prescribed by your 
doctor. </p>
<p>If you take other medicines, which can increase the effects of Jinarc you may receive lower doses. In 
this case your doctor may prescribe you Jinarc tablets with 30 mg or 15 mg tolvaptan which have to be 
taken once a day in the morning. </p>
<p>Method of administration </p>
<p>Swallow the tablets without chewing, with a glass of water. 
The morning dose is to be taken at least 30 minutes before the morning meal. The second daily dose can 
be taken with or without food. </p>
<p>If you take more Jinarc than you should 
If you have taken more tablets than your prescribed dose, drink plenty of water and contact your 
doctor or your local hospital immediately. Remember to take the medicine pack with you so that it is 
clear what you have taken. If you take the higher dose very late in the day you may have to go to the 
toilet at night more frequently. </p>
<p>If you forget to take Jinarc 
If you forget to take your medicine, you should take the dose as soon as you remember on the same day. 
If you do not take your tablets on one day, take your normal dose on the next day. DO NOT take a 
double dose to make up for forgotten individual doses. </p>
<p>If you stop taking Jinarc 
If you stop taking this medicine your kidney cysts may grow as fast as they did before you started 
treatment with Jinarc. Therefore, you should only stop taking this medicine if you notice side effects 
requiring urgent medical attention (see section 4) or if your doctor tells you to. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Serious side effects: </p>
<p>If you notice any of the following side effects, you may need urgent medical attention. Stop taking 
Jinarc and immediately contact a doctor or go to the nearest hospital if you: 
* find it difficult to urinate. 
* experience swelling of the face, lips or tongue, itching, generalised rash, or severe wheezing or 
breathlessness (symptoms of an allergic reaction). </p>
<p>Jinarc may cause your liver not to work properly. 
Consult your doctor if symptoms of nausea, vomiting, fever, tiredness, loss of appetite, pain in the 
abdomen, dark urine, jaundice (yellowing of skin or eyes), itching of your skin or joint and muscle pain 
with fever occur. </p>
<p>Other side effects: </p>
<p>Very common (may affect more than 1 in 10 people) 
* thirst (requiring excessive drinking of water) 
* headache 
* dizziness 
* diarrhoea 
* dry mouth 
* increased need to urinate, to urinate at night, or to urinate more frequently 
* fatigue </p>
<p>Common (may affect up to 1 in 10 people) 
* dehydration 
* high levels of sodium, uric acid and blood sugar 
* decreased appetite 
* taste changes 
* gout 
* difficulty sleeping 
* fainting 
* heart pounding 
* shortness of breath 
* belly pain 
* full or bloated or uncomfortable feeling in the stomach 
* constipation 
* heartburn 
* liver function abnormal 
* dry skin 
* rash 
* itching 
* hives 
* joint pain 
* muscle spasms 
* muscle pain 
* general weakness 
* raised levels of liver enzymes in the blood 
* weight loss 
* weight gain </p>
<p>Uncommon (may affect up to 1 in 100 people) 
* increase of bilirubin (a substance that can cause yellowing of skin or eyes) in the blood </p>
<p>Not known (frequency cannot be estimated from the available data) 
* allergic reactions (see above) 
* generalised rash 
* acute liver failure (ALF) </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not 
listed in this leaflet. You can also report side effects directly via the national reporting system listed in 
Appendix V. By reporting side effects you can help provide more information on the safety of this 
medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store jinarc"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store jinarc"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date, which is stated on the carton, wallet card and the blister 
after EXP. The expiry date refers to the last day of that month. </p>
<p>Store in the original package in order to protect from light and moisture. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Jinarc contains </p>
<ul>
<li>
<p>The active substance is tolvaptan. 
Each Jinarc 15 mg tablet contains 15 mg tolvaptan. 
Each Jinarc 30 mg tablet contains 30 mg tolvaptan. 
Each Jinarc 45 mg tablet contains 45 mg tolvaptan. 
Each Jinarc 60 mg tablet contains 60 mg tolvaptan. 
Each Jinarc 90 mg tablet contains 90 mg tolvaptan. </p>
</li>
<li>
<p>The other ingredients are lactose monohydrate (see section 2), maize starch, microcrystalline 
cellulose, hydroxypropylcellulose, magnesium stearate, indigo carmine aluminium lake. </p>
</li>
</ul>
<p>What Jinarc looks like and contents of the pack </p>
<p>The different strengths of Jinarc tablets have different shapes and embossing: 
15 mg tablet: blue, triangular, debossed with  OTSUKA  and  15  on one side. 
30 mg tablet: blue, round, debossed with  OTSUKA  and  30  on one side. 
45 mg tablet: blue, square, debossed with  OTSUKA  and  45  on one side 
60 mg tablet: blue, modified rectangular, debossed with  OTSUKA  and  60  on one side 
90 mg tablet: blue, pentagonal, debossed with  OTSUKA  and  90  on one side </p>
<p>Your medicine is supplied in the following pack sizes: </p>
<p>Jinarc 15 mg tablets: packs containing 7 tablets or 28 tablets </p>
<p>Jinarc 30 mg tablets: packs containing 7 tablets or 28 tablets </p>
<p>Jinarc 45 mg tablets + Jinarc 15 mg tablets: packs (blisters with or without wallet card) containing 
14 tablets (7 tablets of the higher strength + 7 tablets of the lower strength), 
28 tablets (14 tablets of the higher strength + 14 tablets of the lower strength) or 
56 tablets (28 tablets of the higher strength + 28 tablets of the lower strength). </p>
<p>Jinarc 60 mg tablets + Jinarc 30 mg tablets: packs (blisters with or without wallet card) containing 
14 tablets (7 tablets of the higher strength + 7 tablets of the lower strength), 
28 tablets (14 tablets of the higher strength + 14 tablets of the lower strength) or 
56 tablets (28 tablets of the higher strength + 28 tablets of the lower strength). </p>
<p>Jinarc 90 mg tablets + Jinarc 30 mg tablets: packs (blisters with or without wallet card) containing 
14 tablets (7 tablets of the higher strength + 7 tablets of the lower strength), 
28 tablets (14 tablets of the higher strength + 14 tablets of the lower strength) or 
56 tablets (28 tablets of the higher strength + 28 tablets of the lower strength). </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder </p>
<p>Otsuka Pharmaceutical Netherlands B.V. 
Herikerbergweg 1101 CT, Amsterdam 
Netherlands </p>
<p>Manufacturer </p>
<p>Almac Pharma Services (Ireland) Limited 
Finnabair Industrial Estate, Dundalk, Co. Louth - A91 P9KD 
Ireland </p>
<p>Millmount Healthcare Limited 
Block-7, City North Business Campus, Stamullen, Co. Meath, K32 YDIreland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Otsuka Pharmaceutical Netherlands B.V. 
T l/Tel: +31 (0) 20 85 46 Lietuva 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 <br />
Otsuka Pharmaceutical Netherlands B.V. 
Te : +31 (0) 20 85 46 Luxembourg/Luxemburg 
Otsuka Pharmaceutical Netherlands B.V. 
T l/Tel: +31 (0) 20 85 46  esk  republika 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Magyarorsz g 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Danmark 
Otsuka Pharma Scandinavia AB 
Tlf: +46 (0) 8 545 286 Malta 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Deutschland 
Otsuka Pharma GmbH 
Tel: +49 (0) 69 1700 Nederland 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Eesti 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Norge 
Otsuka Pharma Scandinavia AB 
Tlf: +46 (0) 8 545 286 <br />
Otsuka Pharmaceutical Netherlands B.V. 
Th : +31 (0) 20 85 46  sterreich 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Espa a 
Otsuka Pharmaceutical S.A 
Tel: +34 (0) 93 208 1Polska 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 France 
Otsuka Pharmaceutical France SAS 
T l: +33 (0) 1 47 08 00 Portugal 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Hrvatska 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Rom nia 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Ireland 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Slovenija 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46  sland 
Otsuka Pharma Scandinavia AB 
S mi: +46 (0) 8 545 286 Slovensk  republika 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Italia 
Otsuka Pharmaceutical Italy S.r.l. 
Tel: +39 (0) 2 0063 2Suomi/Finland 
Otsuka Pharma Scandinavia AB 
Puh/Tel: +46 (0) 8 545 286 <br />
Otsuka Pharmaceutical Netherlands B.V. 
Th : +31 (0) 20 85 46 Sverige 
Otsuka Pharma Scandinavia AB 
Tel: +46 (0) 8 545 286 Latvija 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 United Kingdom (Northern Ireland) 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-3441cbef7f1604451bb170e82be4a4ea
InstanceOf: CompositionUvEpi
Title: "Composition for jinarc Package Leaflet"
Description:  "Composition for jinarc Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1ef6cbb5149202df9e76eceb675263a5)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - jinarc"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Jinarc 
3. Sådan skal du tage Jinarc 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What jinarc is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What jinarc is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Jinarc indeholder det aktive stof tolvaptan, som blokerer virkningen af vasopressin, et hormon, der 
medvirker til at danne cyster i nyrerne hos ADPKD-patienter. Ved at blokere virkningen af 
vasopressin bremser Jinarc udviklingen af nyrecyster hos patienter med ADPKD, reducerer 
sygdomssymptomer og øger urinproduktionen. </p>
<p>Jinarc er medicin, der anvendes til at behandle en sygdom, der kaldes “autosomal dominant 
polycystisk nyresygdom" (ADPKD). Denne sygdom forårsager vækst af væskefyldte cyster i nyrerne, 
trykker på det omgivende væv og nedsætter nyrefunktionen, hvilket muligvis kan medføre nyresvigt. 
Jinarc anvendes til at behandle ADPKD hos voksne med kronisk nyresygdom (CKD) i stadium 1 til 
4 med tegn på stor sygdomsaktivitet. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take jinarc"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take jinarc"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Jinarc </p>
<ul>
<li>
<p>hvis du er allergisk over for tolvaptan eller et af de øvrige indholdsstoffer (angivet i punkt 6) ), 
eller hvis du er allergisk over for benzazepin eller benzazepinderivater (f.eks. benazepril, 
conivaptan, fenoldopammesylat eller mirtazapin). </p>
</li>
<li>
<p>hvis du har fået at vide, at du har forhøjede niveauer af leverenzymer i blodet, som ikke tåler 
behandling med tolvaptan. </p>
</li>
<li>
<p>hvis dine nyrer ikke fungerer (ingen produktion af urin). </p>
</li>
<li>
<p>hvis du har en sygdom, der er forbundet med et meget lavt blodvolumen (f.eks. svær 
dehydrering eller blødning). </p>
</li>
<li>
<p>hvis du har en sygdom, der øger saltindholdet i dit blod. </p>
</li>
<li>
<p>hvis du ikke kan føle tørst. </p>
</li>
<li>
<p>hvis du er gravid. </p>
</li>
<li>
<p>hvis du ammer. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, før du tager Jinarc: </p>
<ul>
<li>
<p>hvis du har en leversygdom. </p>
</li>
<li>
<p>hvis du ikke kan drikke nok vand (se “Drik tilstrækkeligt med vand" nedenfor), eller hvis dit 
væskeindtag skal begrænses. </p>
</li>
<li>
<p>hvis du har besvær med at lade vandet (f.eks. pga. forstørret blærehalskirtel (prostata)). </p>
</li>
<li>
<p>hvis du har for højt eller for lavt saltindhold i blodet. </p>
</li>
<li>
<p>hvis du tidligere har haft en allergisk reaktion over for benzazepin, tolvaptan eller andre 
benzazepinderivater (f.eks. benazepril, conivaptan, fenoldopammesylat eller mirtazapin) eller et 
af de øvrige indholdsstoffer (anført i pkt. 6). </p>
</li>
<li>
<p>hvis du har sukkersyge. </p>
</li>
<li>
<p>hvis du har fået at vide, at du har høje niveauer af urinsyre i blodet (som kan have forårsaget 
podagra-anfald). </p>
</li>
<li>
<p>hvis du har en fremskreden nyresygdom. </p>
</li>
</ul>
<p>Dette lægemiddel kan bevirke, at din lever ikke fungerer rigtigt. Derfor skal du straks kontakte 
din læge, hvis du har symptomer, som kunne indikere mulige leverproblemer som f.eks.: </p>
<ul>
<li>
<p>kvalme </p>
</li>
<li>
<p>opkastning </p>
</li>
<li>
<p>feber </p>
</li>
<li>
<p>træthed </p>
</li>
<li>
<p>tab af appetit </p>
</li>
<li>
<p>smerter i maven </p>
</li>
<li>
<p>mørk urin </p>
</li>
<li>
<p>gulsot (gulfarvning af hud eller øjne) </p>
</li>
<li>
<p>kløe på huden </p>
</li>
<li>
<p>influenzalignende syndrom (led- og muskelsmerter med feber) </p>
</li>
</ul>
<p>Under behandling med dette lægemiddel vil din læge arrangere månedlige blodprøver for at 
kontrollere for ændringer i din leverfunktion. </p>
<p>Drik tilstrækkeligt med vand </p>
<p>Dette lægemiddel medfører vandtab, fordi det øger din urinproduktion. Dette vandtab kan medføre 
bivirkninger som mundtørhed og tørst eller endnu alvorligere bivirkninger som f.eks. nyreproblemer 
(se punkt 4). Det er derfor vigtigt, at du har adgang til vand, og at du er i stand til at drikke 
tilstrækkelige mængder, når du er tørstig. Før sengetid skal du drikke 1 eller 2 glas vand, selvom du 
ikke er tørstig, og du skal også drikke vand, efter at du har ladet vandet om natten. Der skal udvises 
særlig forsigtighed, hvis du har en sygdom, som forhindrer tilstrækkeligt væskeindtag, eller hvis du er 
udsat for en øget risiko for vandtab, f.eks. i tilfælde af opkastning eller diarré. På grund af den øgede 
urinproduktion er det også vigtigt, at du altid har adgang til et toilet. </p>
<p>Børn og unge 
Giv ikke dette lægemiddel til børn og unge (under 18 år), da det ikke er undersøgt hos disse 
aldersgrupper. </p>
<p>Brug af anden medicin sammen med Jinarc 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden 
medicin eller planlægger at tage anden medicin. Dette gælder også medicin, som ikke er købt på 
recept. </p>
<p>Følgende lægemidler kan øge virkningen af Jinarc: </p>
<ul>
<li>
<p>amprenavir, atazanavir, darunavir/ritonavir og fosamprenavir (anvendes til at behandle hiv/aids) </p>
</li>
<li>
<p>aprepitant (anvendes til at undgå kvalme og opkastning ved kemoterapi) </p>
</li>
<li>
<p>crizotinib og imatinib (anvendes til at behandle kræft) </p>
</li>
<li>
<p>ketoconazol, fluconazol eller itraconazol (anvendes til at behandle svampeinfektioner) </p>
</li>
<li>
<p>makrolidantibiotika som f.eks. erythromycin eller clarithromycin </p>
</li>
<li>
<p>verapamil (anvendes til at behandle hjertesygdomme og forhøjet blodtryk)  </p>
</li>
<li>
<p>ciprofloxacin (et antibiotisk middel) </p>
</li>
<li>
<p>diltiazem (anvendes til at behandle forhøjet blodtryk og brystsmerter). </p>
</li>
</ul>
<p>Følgende lægemidler kan reducere virkningen af Jinarc: </p>
<ul>
<li>
<p>phenytoin eller carbamazepin (anvendes til at behandle epilepsi) </p>
</li>
<li>
<p>rifampicin, rifabutin eller rifapentin (anvendes til at behandle tuberkulose) </p>
</li>
<li>
<p>prikbladet perikum (traditionel urtemedicin til lindring af let depression og angst). </p>
</li>
</ul>
<p>Jinarc kan øge virkningen af følgende lægemidler: </p>
<ul>
<li>
<p>digoxin (anvendes til at behandle uregelmæssigt hjerteslag og hjertesvigt) </p>
</li>
<li>
<p>dabigatran (blodfortyndende middel) </p>
</li>
<li>
<p>sulfasalazin (anvendes til at behandle betændelse i tyktarmen eller reumatoid artritis) </p>
</li>
<li>
<p>metformin (anvende til at behandle diabetes). </p>
</li>
</ul>
<p>Jinarc kan reducere virkningen af følgende lægemidler: </p>
<ul>
<li>vasopressin-analoger som f.eks. desmopressin (benyttes til at øge koagulationsfaktorerne i 
blodet eller regulere urinproduktionen eller ved ufrivillig natlig vandladning). </li>
</ul>
<p>Disse lægemidler kan påvirke eller blive påvirket af Jinarc: </p>
<ul>
<li>
<p>diuretika (anvendes til at øge urinproduktionen). Hvis disse tages sammen med Jinarc, kan de 
øge risikoen for bivirkninger på grund af vandtab eller forårsage nyreproblemer. </p>
</li>
<li>
<p>diuretika og andre lægemidler til behandling af forhøjet blodtryk. Hvis disse tages sammen med 
Jinarc, kan de øge risikoen for lavt blodtryk, når du rejser dig fra siddende eller liggende 
stilling. </p>
</li>
<li>
<p>lægemidler, der øger niveauet af natrium i blodet, eller som indeholder store mængder salt 
(f.eks. tabletter, der opløses i vand, og fordøjelsesmidler). Disse kan øge virkningen af Jinarc. 
Der er risiko for, at dette kan medføre for meget natrium i dit blod. </p>
</li>
</ul>
<p>Du kan måske alligevel godt tage disse lægemidler sammen med Jinarc. Din læge vil kunne afgøre, 
hvad der er egnet til dig. </p>
<p>Brug af Jinarc sammen med mad og drikke 
Du må ikke drikke grapefrugtjuice, når du tager dette lægemiddel. </p>
<p>Graviditet og amning 
Tag ikke dette lægemiddel, hvis du er gravid eller ammer. </p>
<p>Kvinder i den fertile alder skal anvende sikker kontraception under behandlingen med Jinarc. </p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed 
Nogle mennesker kan føle sig svimle, svage eller trætte, efter at de har taget Jinarc. Kør ikke bil eller 
motorcykel og lad være med at cykle eller arbejde med værktøj eller maskiner, hvis dette er tilfældet 
for dig. </p>
<p>Jinarc indeholder lactose 
Kontakt lægen, før du tager denne medicin, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take jinarc"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take jinarc"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Jinarc må kun ordineres af læger, som har specialkundskab inden for ADPKD. Tag altid dette 
lægemiddel nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller på apoteket. </p>
<p>Dosis </p>
<p>Den daglige mængde Jinarc skal deles i to doser, den ene større end den anden. Den højeste dosis skal 
tages om morgenen, når du vågner, mindst 30 minutter før morgenmaden. Den laveste dosis tages 
8 timer senere. </p>
<p>Dosiskombinationerne er: 
45 mg + 15 mg 
60 mg + 30 mg 
90 mg + 30 mg </p>
<p>Din behandling vil normalt begynde med en dosis på 45 mg om morgenen og 15 mg 8 timer senere. 
Din læge kan øge din dosis gradvist til en maksimal kombination på 90 mg, når du vågner og 30 mg 
efter 8 timer. For at finde den bedste dosis vil din læge jævnligt kontrollere, hvor godt du kan tåle en 
ordineret dosis. Du skal altid tage den højeste dosiskombination, du kan tåle, og som din læge har 
ordineret. </p>
<p>Hvis du tager andre lægemidler, som kan øge virkningen af Jinarc, kan du eventuelt få lavere doser. I 
dette tilfælde kan din læge ordinere Jinarc tabletter med 30 mg eller 15 mg tolvaptan, som skal tages 
én gang dagligt om morgenen. </p>
<p>Administration </p>
<p>Tabletterne sluges hele med et glas vand. 
Morgendosis skal tages mindst 30 minutter før morgenmaden. Den anden daglige dosis kan tages 
sammen med eller uden mad. </p>
<p>Hvis du har taget for meget Jinarc 
Hvis du har taget flere tabletter end den ordinerede dosis, skal du straks drikke rigeligt med vand og 
kontakte din læge eller nærmeste hospital. Husk at tage medicinens emballage med, så de ved, hvad 
du har taget. Hvis du tager den højeste dosis meget sent på dagen, kan det være, at du skal på toilettet 
hyppigere om natten. </p>
<p>Hvis du har glemt at tage Jinarc 
Hvis du har glemt at tage din medicin, skal du tage dosis, så snart du husker det samme dag. Hvis du 
glemmer at tage dine tabletter den ene dag, skal du tage den normale dosis den næste dag. Du må 
IKKE tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du holder op med at tage Jinarc 
Hvis du holder op med at tage dette lægemiddel, kan dine cyster vokse lige så hurtigt, som de gjorde, 
før du begyndte at blive behandlet med Jinarc. Derfor bør du kun holde op med at tage dette 
lægemiddel, hvis du får bivirkninger, der kræver akut lægehjælp (se pkt. 4) eller hvis din læge har 
sagt, at du skal stoppe. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Alvorlige bivirkninger: </p>
<p>Hvis du bemærker en eller flere af følgende bivirkninger, kan du få brug for akut lægehjælp. 
Hold op med at tage Jinarc og kontakt straks en læge eller nærmeste hospital, hvis du: </p>
<ul>
<li>
<p>har svært ved at lade vandet. </p>
</li>
<li>
<p>opdager hævelse i ansigtet, på læberne eller på tungen, hvis du har kløe, generaliseret udslæt 
eller hvæsende vejrtrækning eller åndenød (symptomer på en allergisk reaktion). </p>
</li>
</ul>
<p>Jinarc kan bevirke, at din lever ikke fungerer rigtigt. 
Kontakt din læge, hvis du oplever symptomer som kvalme, opkastning, feber, træthed, appetitløshed, 
mavesmerter, mørk urin, gulsot (gulfarvning af hud og øjne), kløende hud eller led- og muskelsmerter 
med feber. </p>
<p>Andre bivirkninger: </p>
<p>Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer) </p>
<ul>
<li>
<p>tørst (der gør det nødvendigt at drikke store mængder vand) </p>
</li>
<li>
<p>hovedpine </p>
</li>
<li>
<p>svimmelhed </p>
</li>
<li>
<p>diarré </p>
</li>
<li>
<p>mundtørhed </p>
</li>
<li>
<p>større behov for at lade vandet eller oftere vandladning </p>
</li>
<li>
<p>træthed </p>
</li>
</ul>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 personer) </p>
<ul>
<li>
<p>dehydrering </p>
</li>
<li>
<p>højt indhold af natrium, urinsyre og sukker i blodet </p>
</li>
<li>
<p>nedsat appetit </p>
</li>
<li>
<p>smagsforstyrrelser </p>
</li>
<li>
<p>urinsyregigt </p>
</li>
<li>
<p>søvnproblemer </p>
</li>
<li>
<p>besvimelse </p>
</li>
<li>
<p>hjertebanken </p>
</li>
<li>
<p>åndenød </p>
</li>
<li>
<p>mavesmerter </p>
</li>
<li>
<p>følelse af mæthed eller ubehag i maven </p>
</li>
<li>
<p>forstoppelse </p>
</li>
<li>
<p>halsbrand </p>
</li>
<li>
<p>unormal leverfunktion </p>
</li>
<li>
<p>tør hud </p>
</li>
<li>
<p>udslæt </p>
</li>
<li>
<p>kløe </p>
</li>
<li>
<p>nældefeber </p>
</li>
<li>
<p>ledsmerter </p>
</li>
<li>
<p>muskelkramper </p>
</li>
<li>
<p>muskelsmerter </p>
</li>
<li>
<p>almen svaghed </p>
</li>
<li>
<p>forhøjede niveauer af leverenzymer i blodet </p>
</li>
<li>
<p>vægttab </p>
</li>
<li>
<p>vægtøgning </p>
</li>
</ul>
<p>Ikke almindelig (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>forhøjet bilirubin (et stof, der kan forårsage gulfarvning af hud eller øjne) i blodet </li>
</ul>
<p>Ikke kendt (hyppighed kan ikke estimeres ud fra forhåndenværende data) </p>
<ul>
<li>
<p>allergiske reaktioner (se ovenfor) </p>
</li>
<li>
<p>generaliseret udslæt </p>
</li>
<li>
<p>akut leversvigt </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store jinarc"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store jinarc"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken, etuiet eller blisteren efter “EXP". 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevares i den originale yderpakning for at beskytte mod lys og fugt. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Jinarc indeholder </p>
<ul>
<li>
<p>Aktivt stof: tolvaptan. 
Hver 15 mg tablet indeholder 15 mg tolvaptan. 
Hver 30 mg tablet indeholder 30 mg tolvaptan. 
Hver 45 mg tablet indeholder 45 mg tolvaptan. 
Hver 60 mg tablet indeholder 60 mg tolvaptan. 
Hver 90 mg tablet indeholder 90 mg tolvaptan. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: lactosemonohydrat (se punkt 2), majsstivelse, mikrokrystallinsk 
cellulose, hydroxypropylcellulose, magnesiumstearat, indigocarmin aluminium lake (E 132). </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Jinarc tabletternes forskellige styrker har forskellige former og prægning: 
15 mm tablet: blå, trekantet, præget med “OTSUKA" og “15" på den ene side. 
30 mm tablet: blå, rund, præget med “OTSUKA" og “30" på den ene side. 
45 mm tablet: blå, firkantet, præget med “OTSUKA" og “45" på den ene side. 
60 mm tablet: blå, modificeret rektangulær, præget med “OTSUKA" og “60" på den ene side. 
90 mm tablet: blå, femkantet, præget med “OTSUKA" og “90" på den ene side. </p>
<p>Din medicin leveres i følgende pakningsstørrelser: </p>
<p>Jinarc 15 mg tabletter: pakninger indeholdende 7 tabletter eller 28 tabletter </p>
<p>Jinarc 30 mg tabletter: pakninger indeholdende 7 tabletter eller 28 tabletter </p>
<p>Jinarc 45 mg tabletter + Jinarc 15 mg tabletter: pakninger (blistre med eller uden etui) indeholdende 
14 tabletter (7 tabletter i den højeste styrke + 7 tabletter i den laveste styrke), 
28 tabletter (14 tabletter i den højeste styrke + 14 tabletter i den laveste styrke) eller 
56 tabletter (28 tabletter i den højeste styrke + 28 tabletter i den laveste styrke). </p>
<p>Jinarc 60 mg tabletter + Jinarc 30 mg tabletter: pakninger (blistre med eller uden etui) indeholdende 
14 tabletter (7 tabletter i den højeste styrke + 7 tabletter i den laveste styrke), 
28 tabletter (14 tabletter i den højeste styrke + 14 tabletter i den laveste styrke) eller 
56 tabletter (28 tabletter i den højeste styrke + 28 tabletter i den laveste styrke). </p>
<p>Jinarc 90 mg tabletter + Jinarc 30 mg tabletter: pakninger (blistre med eller uden etui) indeholdende 
14 tabletter (7 tabletter i den højeste styrke + 7 tabletter i den laveste styrke), 
28 tabletter (14 tabletter i den højeste styrke + 14 tabletter i den laveste styrke) eller 
56 tabletter (28 tabletter i den højeste styrke + 28 tabletter i den laveste styrke). </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Otsuka Pharmaceutical Netherlands B.V. 
Herikerbergweg 1101 CT, Amsterdam 
Holland </p>
<p>Fremstiller </p>
<p>Almac Pharma Service (Ireland) Limited 
Finnabair Industrial Estate, Dundalk, Co. Louth - A91 P9KD 
Irland </p>
<p>Millmount Healthcare Limited 
Block-7, City North Business Campus, Stamullen, Co. Meath, K32 YDIrland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Otsuka Pharmaceutical Netherlands B.V. 
Tél/Tel: +31 (0) 20 85 46<br />
Lietuva 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 България 
Otsuka Pharmaceutical Netherlands B.V. 
Teл: +31 (0) 20 85 46<br />
Luxembourg/Luxemburg 
Otsuka Pharmaceutical Netherlands B.V. 
Tél/Tel: +31 (0) 20 85 46 Česká republika 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Magyarország 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Danmark 
Otsuka Pharma Scandinavia AB 
Tlf: +46854 528<br />
Malta 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Deutschland 
Otsuka Pharma GmbH 
Tel: +49691 700<br />
Nederland 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Eesti 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Norge 
Otsuka Pharma Scandinavia AB 
Tlf: +46854 528 Ελλάδα 
Otsuka Pharmaceutical Netherlands B.V. 
Thλ: +31 (0) 20 85 46<br />
Österreich 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 España 
Otsuka Pharmaceutical S.A 
Tel: +3493 2081<br />
Polska 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 France 
Otsuka Pharmaceutical France SAS 
Tél: +33147 080<br />
Portugal 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Hrvatska 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
România 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Ireland 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Slovenija 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Ísland 
Otsuka Pharma Scandinavia AB 
Sími: +46854 528<br />
Slovenská republika 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46 Italia 
Otsuka Pharmaceutical Italy S.r.l. 
Tel: +39 02 00 63 27<br />
Suomi/Finland 
Otsuka Pharma Scandinavia AB 
Puh/Tel: +46854 528 Κύπρος 
Otsuka Pharmaceutical Netherlands B.V. 
Thλ: +31 (0) 20 85 46<br />
Sverige 
Otsuka Pharma Scandinavia AB 
Tel: +46854 528<br />
Latvija 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
United Kingdom (Northern Ireland) 
Otsuka Pharmaceutical Netherlands B.V. 
Tel: +31 (0) 20 85 46<br />
Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-3441cbef7f1604451bb170e82be4a4ea
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for jinarc Package Leaflet for language en"
Description: "ePI document Bundle for jinarc Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-3441cbef7f1604451bb170e82be4a4ea"
* entry[0].resource = composition-en-3441cbef7f1604451bb170e82be4a4ea

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3441cbef7f1604451bb170e82be4a4ea"
* entry[=].resource = mp3441cbef7f1604451bb170e82be4a4ea
                            
                    
Instance: bundlepackageleaflet-da-3441cbef7f1604451bb170e82be4a4ea
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for jinarc Package Leaflet for language da"
Description: "ePI document Bundle for jinarc Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-3441cbef7f1604451bb170e82be4a4ea"
* entry[0].resource = composition-da-3441cbef7f1604451bb170e82be4a4ea

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp3441cbef7f1604451bb170e82be4a4ea"
* entry[=].resource = mp3441cbef7f1604451bb170e82be4a4ea
                            
                    



Instance: mp3441cbef7f1604451bb170e82be4a4ea
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product jinarc"
Description: "jinarc"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Jinarc 15 mg tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "jinarc"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 3441cbef7f1604451bb170e82be4a4eaListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "jinarc"

* status = #current
* mode = #working

* title = "List of all ePIs associated with jinarc"

* subject = Reference(mp1ef6cbb5149202df9e76eceb675263a5)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#jinarc "jinarc"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-3441cbef7f1604451bb170e82be4a4ea) // jinarc en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-3441cbef7f1604451bb170e82be4a4ea) // jinarc da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-3441cbef7f1604451bb170e82be4a4ea
InstanceOf: List

* insert 3441cbef7f1604451bb170e82be4a4eaListRuleset
    